Physician Knowledge and Awareness of CA-125 as a Screen for Ovarian Cancer in the Asymptomatic, Average-Risk Population

被引:4
|
作者
Stewart, Sherri L. [1 ]
Rim, Sun Hee [1 ]
Gelb, Cynthia A. [1 ]
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA
关键词
CA-125; ovarian cancer; screen; ELECTIVE OOPHORECTOMY; DIAGNOSTIC MARKERS; WOMEN; DISEASE; SERUM; HYSTERECTOMY; MAMMOGRAPHY; MENOPAUSE; BEHAVIOR; THERAPY;
D O I
10.1177/1090198111407185
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Effective early detection strategies for ovarian cancer do not exist. Current screening guidelines recommend against routine screening using CA-125 alone or in combination with transvaginal ultrasonography (TVS). In this study, the authors used the 2008 DocStyles survey to measure clinician beliefs about the effectiveness of CA-125 and TVS in the asymptomatic, average-risk population in the United States. To assess the need for provider education, the authors used the 2008 HealthStyles survey to examine public awareness of CA-125. Of 1,250 physician respondents, 40.4% said both CA-125 and TVS were effective screens, and 28.3% said neither was an effective ovarian cancer screen in the asymptomatic, average-risk population. Obstetrician/gynecologists [OB/GYNs] more often had responses consistent with current guidelines: 56.5% of OB/GYNs, compared with 34.4% and 29.8% of family/general practitioners and internists, respectively, said neither CA-125 nor TVS was an effective screen. Almost one third of women surveyed reported having heard of CA-125, and about one tenth said they had the CA-125 test. These findings support the need for additional provider education. Educational efforts should include lack of evidence for, as well as the potential harms of, screening for ovarian cancer with CA-125.
引用
收藏
页码:57 / 66
页数:10
相关论文
共 50 条
  • [1] Normal CA-125 and the risk of progression in ovarian cancer
    Markman, Maurie
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (20) : 3310 - 3310
  • [2] CA-125 IN OVARIAN-CANCER
    VANDERBURG, MEL
    LAMMES, FB
    VERWEIJ, J
    NETHERLANDS JOURNAL OF MEDICINE, 1992, 40 (1-2): : 36 - 51
  • [3] Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
    Markmann, M
    Liu, PY
    Rothenberg, ML
    Monk, BJ
    Brady, M
    Alberts, DS
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1454 - 1458
  • [4] Causes of asymptomatic CA-125 elevation in the general population
    Park, J.
    Kim, K.
    Kim, J.
    Kim, M.
    Chung, H.
    Kim, J.
    Park, N.
    Song, Y.
    Kang, S.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S106 - S107
  • [5] OVARIAN-CANCER, INFLAMMATION, AND CA-125
    MARKMAN, M
    HOSKINS, WB
    ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) : 1049 - 1049
  • [6] USE OF CA-125 IN THE MANAGEMENT OF OVARIAN CANCER
    Mahner, S.
    Sehouli, J.
    Woelber, L.
    Jaenicke, F.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4033 - 4034
  • [7] CA-125 AND SURVIVAL IN OVARIAN-CANCER
    PARKER, D
    PATEL, K
    ALRED, EJ
    HARNDENMAYOR, P
    NAYLOR, B
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (01) : 22 - 22
  • [8] CA-125 AND SURVIVAL IN OVARIAN-CANCER
    PARKER, D
    PATEL, K
    ALRED, J
    HARNDENMAYOR, P
    NAYLOR, B
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 233 - 234
  • [9] The Management of Anxiety and Knowledge of Serum CA-125 After an Ovarian Cancer Diagnosis
    Reid, Amanda
    Ercolano, Elizabeth
    Schwartz, Peter
    McCorkle, Ruth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2011, 15 (06) : 625 - 632
  • [10] Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults
    Mayer, Martin
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (04)